Clinical trials: Peritoneal Cancer
Ovarian Cancer, Fallopian Tube Cancer
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT03635489
- Testing
- Paclitaxel, Bevacizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
This study tests whether denileukin diftitox will deplete regulatory T cells, boost tumor-specific immunity and treat epithelial ovarian cancer in patients who have failed, or who are ineligible for front line therapy.
- Conditions
- Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
- Trial name
- ONTAK (NCT00880360)
- Testing
- Ontak
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
This phase II trial studies the side effects and how well selumetinib sulfate works in treating patients with low-grade ovarian cancer that has come back (recurrent).
- Conditions
- Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma, Micropapillary Serous Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- NCT00551070
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib
- Where
- 49 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
This phase II trial studies the side effects and how well dalantercept works in treating patients with ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer that has returned.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01720173
- Testing
- Dalantercept, Laboratory Biomarker Analysis
- Where
- 40 sites in United States
- Volunteers
- 30 people
- Sponsor
- Gynecologic Oncology Group
FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer
This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian…
- Conditions
- FIGO Stage III and IV Ovarian Cancer, FIGO Stage III and IV Fallopian Tube Cancer, FIGO Stage III Primary Peritoneal Cancer
- Trial name
- NCT03054909
- Testing
- ALT-803 Subcutaneous, ALT-803 Intraperitoneal
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well paclitaxel when given together with or without pazopanib hydrochloride works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01468909
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pazopanib Hydrochloride
- Where
- 142 sites in United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Peritoneal Cavity Cancer
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00538031
- Testing
- cyclophosphamide, celecoxib
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- City of Hope Medical Center
Ovarian Cancer, Primary Peritoneal Carcinoma
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
The main purpose of this trial is to look at how elderly women (70 years of age or older) with newly diagnosed ovarian, peritoneal, or fallopian tube cancer manage six cycles of carboplatin and paclitaxel, what side effects they…
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Mixed Tumor, Mesodermal
- Trial name
- NCT00322881
- Testing
- Paclitaxel, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT00096200
- Testing
- Carboplatin, Paclitaxel, Sorafenib Tosylate
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
S9912 Combination Chemo in Stage III Ovarian Cancer,
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003896
- Testing
- cisplatin, liposomal doxorubicin, paclitaxel
- Where
- 104 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Ovarian Neoplasms
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
The purpose of this project is to determine if a new combination of drugs, erlotinib (Tarceva™) and bevacizumab is safe and effective for treating women diagnosed with ovarian cancer whose cancer has progressed while on prior…
- Trial name
- NCT00130520
- Testing
- bevacizumab, erlotinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Arizona
Ovarian Cancer, Primary Peritoneal Cancer
Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This will be a non-blinded, single arm study to test the efficacy of Regorafenib in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02278783
- Testing
- regorafenib
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Utah
Ovarian Neoplasms, Peritoneal Neoplasms
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a third-line chemotherapy regimen (treatment) in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01846611
- Testing
- Trabectedin, DOXIL, Dexamethasone
- Where
- 138 sites in United States, Australia and 8 more
- Volunteers
- 581 people
- Sponsor
- Janssen Research & Development, LLC
Fallopian Tube Cancer, Ovarian Cancer
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00522301
- Testing
- sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
Feasibility study to assess a novel combination of cytotoxic agents, docetaxel and oxaliplatin, as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis…
- Trial name
- TEACO (NCT00296816)
- Testing
- Bevacizumab (Avastin®), Docetaxel (Taxotere®), Oxaliplatin (Eloxatin®)
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Sanofi
Peritoneal Carcinomatosis
Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
A randomized controlled single-blind clinical trial was performed, in 32 patients diagnosed with peritoneal carcinomatosis from epithelial ovarian cancer, who underwent radical surgery-peritonectomy, achieving an optimal R0-R1…
- Trial name
- NCT02739698
- Testing
- Paclitaxel, Radical surgery-peritonectomy
- Volunteers
- 32 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Prostate Cancer, Pneumoperitoneum
Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies
The AirSeal® System will allow for lower carbon dioxide (CO2) absorption rates than the standard Endopath System.
- Trial name
- NCT02114164
- Testing
- AirSeal System, Standard Endopath
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- OhioHealth
Gastric Cancer, Peritoneal Carcinomatosis
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
- Trial name
- HIPECStomach (NCT01683864)
- Testing
- positive cytology with HIPEC
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University Hospital Tuebingen